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EMTThe WWP2 E3 ubiquitin ligase has previously been shown to regulate TGFβ/Smad signalling activity linked to
epithelial–mesenchymal transition (EMT). Whilst inhibitory I-Smad7 was found to be the preferred substrate for
full-length WWP2-FL and a WWP2-C isoform, WWP2-FL also formed a stable complex with an N-terminal WWP2
isoform (WWP2-N) in the absence of TGFβ, and rapidly stimulated activating Smad2/3 turnover. Here, using stable
knockdown experiments we show that speciﬁc depletion of individual WWP2 isoforms impacts differentially on
Smad protein levels, and in WWP2-N knockdown cells we unexpectedly ﬁnd spontaneous expression of the EMT
marker vimentin. Re-introduction ofWWP2-N intoWWP2-N knockout cells also repressed TGFβ-induced vimentin
expression. In support of the unique role for WWP2-N in regulating TGFβ/Smad functional activity, we then show
that a novel V717M-WWP2 mutant in the MZ7-mel melanoma cell line forms a stable complex with the WWP2-
N isoform and promotes EMT by stabilizing Smad3 protein levels. Finally, we report the ﬁrst analysis of WWP2 ex-
pression in cancer cDNA panel arrays using WWP2 isoform-speciﬁc probes and identify unique patterns of WWP2
isoform abundance associated with early/advanced disease stages. WWP2-N is signiﬁcantly downregulated in
stage IIIC melanoma and up-regulated in stage II/III prostate cancer, and we also ﬁnd isolated examples of WWP2-
FL and WWP2-C overexpression in early-stage breast cancer. Together, these data suggest that individual WWP2
isoforms, and particularly WWP2-N, could play central roles in tumourigenesis linked to aberrant TGFβ-
dependent signalling function, and also have potential as both prognosticmarkers andmolecular therapeutic targets.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Ubiquitination represents an important post-translational modiﬁca-
tion that controls protein turnover, activity and subcellular localization
[1,2]. Ubiquitin is covalently attached to proteins via a three component
enzymatic cascade involving its sequential transfer from a ubiquitin
activating enzyme (E1) to a ubiquitin conjugating enzyme (E2), and
then onto speciﬁc target substrates via a ubiquitin protein ligase (E3).
There are around 600 E3 ligases in the genome [3], and WWP2 E3
ubiquitin ligase is one of nine related Nedd4 subfamily members, con-
taining an N-terminal Ca2+/phospholipid-binding C2 domain, four
adjacent WW domains and a C-terminal HECT catalytic domain [4,5].
Interestingly, there are three separate WWP2 isoforms encoded within
the WWP2 gene locus including full-length WWP2 (WWP2-FL), an N-
terminal isoform lacking the HECT domain but incorporating a single
WW1 domain, and a C-terminal isoform containing the HECT catalytic
domain and WW4 domain [6,7].
SeveralWWP2 substrates associatedwith tumourigenesis have been
identiﬁed and characterized including the PTEN tumour suppressor and44 1603 592250.
ights reserved.key signalling components within the transforming growth factor-β
(TGFβ) pathway known as Smads, and ectopic WWP2 overexpression
also increased tumour cell spread in animal models [8,9]. Whilst TGFβ
signalling serves a dual biological purpose in that it can cause cells to un-
dergo cell cycle arrest and apoptosis, it also stimulates cells to undergo a
differentiation process known as epithelial mesenchymal transition
(EMT) that drives tumour cell dispersion and metastasis [10,11]. Inter-
estingly, individual WWP2 isoforms have been shown to bind differen-
tially to Smads, providing a novel regulatory mechanism that ﬁne-
tunes the levels of both activating and inhibitory Smads [9]. WWP2-FL
selectively interacted with Smad2, Smad3 and Smad7 following TGFβ
stimulation, and Smad7 is a preferred substrate. However, WWP2-N
was also shown to form a complex with WWP2-FL in the absence of
TGFβ, and dose-dependently activated WWP2-FL to drive rapid degra-
dation of unstimulated Smad2 and Smad3. Following TGFβ stimulation,
thisWWP2-FL/WWP2-N complex rapidly dissociated, and subsequently
switched WWP2-FL substrate speciﬁcity towards inhibitory Smad7.
Thus, WWP2 isoforms have a unique ability to interchange Smad sub-
strate speciﬁcity in the presence/absence of TGFβ, and dependent
upon the expression of individual WWP2 isoforms.
In this study, and in light of their inter-dependent functional roles
in oncogenic signalling mechanisms, we show that WWP2-N stable
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marker vimentin. Furthermore, we identify a mutant form of WWP2
found in the malignant MZ7-mel melanoma cell line that has altered
speciﬁcity towards WWP2-N and R-Smads. The signiﬁcance of WWP2-
N as a key regulator of oncogenic TGFβ/Smad function is further high-
lighted whenwe quantitatively surveyed expression levels of individual
WWP2 isoforms in cDNA arrays derived from breast cancer, prostate
cancer and melanoma. Interestingly, we ﬁnd that the levels of WWP2-
N are signiﬁcantly low in advanced relative to early stages of melanoma
yet high in prostate cancer. Collectively, our data reveal important new
insight into WWP2 isoform function linked to the tumourigenic role of
Smad signalling that warrants further investigation of WWP2 ligase
isoforms as novel cancer prognostic markers and therapeutic targets.2. Materials and methods
2.1. Antibodies, DNA plasmids, reagents
Antibodies used for western blottingwere: Rabbit anti-Smad3 (Chip
grade, Abcam), Rabbit anti-Smad2 (Cell Signalling), Mouse anti-SMAD7
(New England Biolabs), mouse anti-human vimentin (Sigma), mouse
anti-β actin (Sigma), and anti-WWP2-C and anti-WWP2-N (Abcam,
UK), high afﬁnity Rat anti-HA (Roche), and M2 Mouse anti-Flag
(Sigma). Plasmids encoding the Flag-tagged derivatives of human
WWP2, obtained from Fiona McDonald (University of Otago, NZ),
were constructed by PCR cloning into pRK5 followed by the
insertion of the Flag coding sequence at the 5′ terminal [9]. Deriva-
tion of human HA-/Flag-tagged Smad2, Smad3 and Smad7 is
described elsewhere [12]. Human HA-tagged ubiquitin (expressed
in pCDNA3.1+) was a kind gift from Dirk Bohmann (University of
Rochester, USA). MG132 (Sigma) was reconstituted in DMSO and
used at 10 μM, and SB431542 (Tocris Ltd) was used at 10 μM
concentration. Recombinant TGFβ1 was from R&D systems.2.2. Stable knockdown of WWP2 isoforms
Stable expression shRNA encoding plasmids speciﬁc for WWP2
isoforms were generated by annealing and cloning phosphorylated
complementary oligonucleotides into Bgl II cleaved plasmid pTER, and
used to generate stable Colo-357-Tet repressor expressing cells as
described previously [9]. Expression was induced by stimulation of
cells with 2 μM doxycycline (Melford Laboratories) for 48 h. Prior to
lysis cells were washed in cold PBS, lysed in 1% v/v Igepal-630, 50 mM
Tris pH 8.0, 150 mM NaCl, 10% v/v glycerol, 5 mM EDTA, 1 mM NaF,
1 mM Na3VO4 and protease inhibitors (1% NP-40 LB), in the ratio 1
tablet (Roche):30 ml 1% NP-40LB. Lysates were mixed directly with
SDS-PAGE Laemlli buffer (+10 mMDTT), and western blots developed
using ECL reagent. The oligonucleotides used to generate WWP2
isoform shRNA plasmids are deﬁned in Supplementary information.2.3. Immunoprecipitation assays
Transfected cells treated with either 10 μMMG132 for 5 h in DMEM
medium containing 2% FCS and treated +/−5 ng/ml TGFβ for 1 h,
washed in cold PBS, lysed in 1% v/v Igepal-630, 50 mM Tris pH 8.0,
150 mM NaCl, 10% v/v glycerol, 5 mM EDTA, 1 mM NaF, 1 mM
Na3VO4 and protease inhibitors (1% NP-40 LB), in the ratio 1 tablet
(Roche):30 ml 1% NP-40LB. Lysates were cleared by centrifugation
and incubated with 0.5 μg high afﬁnity anti-HA antibody (Roche)
and 20 μl of protein-G agarose (Sigma) overnight at 4 °C. Immune-
complexes were harvested (2000 rpm; 30 s), repeatedly washed using
0.1% NP-40 LB, and resuspended in 15 μl Laemlli buffer (+10 mM
DTT) followed by Western blotting analysis.2.4. Cycloheximide chase experiments
HEK293 cells were transfected and after 48 h were pre-treated with
10 μMMG132 for 5 h in DMEM (+2% serum). Cycloheximide (20 μM)
was added and cells incubated for 1 h. Themediumwas removed and re-
placed with DMEMmedium (+2% serum) and 20 μg/ml cycloheximide,
and cells harvested at speciﬁed time-points. Cells were washed in ice
cold PBS, lysed in 1% NP-40LB and analysed by Western blotting.
2.5. Luciferase reporter assays
The Smad3 reporter construct (pCAGAC12-luc) and the Smad2-
speciﬁc reporter plasmid DE-luc were kindly provided by Caroline
Hill (CRUK Laboratories, UK). For each plasmid transfection,
250 ng pCAGAC12-luc and 15 ng pRSV-β-galactosidase (pRSV-
βgal) encoding plasmid were used in conjunction with Smad
encoding plasmids as described previously [9].
2.6. Induction of EMT in Colo-357 cells
Colo-357 cells were seeded at 104 cells per 35 mm plastic well
(Nunclon) and the next day left unstimulated, stimulated with 5 ng/ml
TGFβ, 5 ng/ml TGFβ + SB431542, and everyday thereafter until day 6
(where the mediumwas changed every 2 days). Cells were then washed
in PBS, lysed in 250 μl 1% NP40-LB to which 250 μl of 2× Laemlli buffer
was added and samples boiled (10 min) and analysed by Western
blotting.
2.7. Growth/survival assays
For growth/survival assays, 2 × 104 cells were seeded per well into
96 well plates and grown in tet approved serum overnight. Cells were
grown for 48 h in the absence or presence of tet and serum starved
for 16 h. Colo-357 cells were treated with TGFβ at 0.5 ng/ml for 48 h,
or were left untreated. At the relevant time point, cell growth/survival
was assessed using the CellTiter 96® One Solution Cell Proliferation
Assay (Promega, UK).
2.8. WWP2 isoform expression analysis in primary tumour samples using
real-time qRT-PCR analysis
ForWWP2 isoform expression analysis in normal and cancer tissues,
Tissue Scan™ tissue quantitative PCR arrays were used according to the
manufacturer's protocol (Origene, Rockville, USA), and data normalised
to β-actin. The array panels consisted of breast cancer cDNA derived
from normal (n = 7), stage I (n = 10), stage IIA (n = 13), stage IIB
(n = 7), stage IIIA (n = 8), stage IIIC (n = 3); melanoma cDNA
from normal (n = 3), stage III (n = 10), stage IIIA (n = 1), stage IIIB
(n =6), stage IIIC (n = 4), stage IV (n = 19); prostate cancer cDNA
from normal (n = 7), stage II (n = 7), stage III (n = 3), and non-
recorded hyperplasia/prostatitis (n = 31). Quantitative qRT-PCR was
performed as described previously [13]. The primer/probe sequences
for detecting WWP2 isoform expression used were designed and
manufactured by Primer Design, Southampton, UK (see Supplementary
information for primer sequences). Cycling conditions were 2 min at
50 °C, 10 min at 95 °C, 15 s at 95 °C repeated 40 times and 60 °C for
1 min. Reactionswere performedusing anABI PRISM7700 thermocycler
(Applied Biosystems).
3. Results
3.1. WWP2 isoform depletion impacts differentially on the levels of Smads
and the EMT marker vimentin
The WWP2 locus encodes three distinct isoforms including full-
length WWP2 (WWP2-FL), an N-terminal isoform lacking the HECT
Fig. 1. Knockdown ofWWP2 isoforms impacts differentially on vimentin, Smad levels and
cell proliferation. (a) Expression of shRNAswas induced by stimulation of cells with 2 μM
doxycycline for 48 h. Lysates were mixed directly with SDS-PAGE Laemlli buffer
(+10 mMDTT), andwestern blots probedwith speciﬁcWWP2-FL andWWP2-N antibod-
ies as indicated and developed using enhanced ECL reagent. The oligonucleotides used to
generateWWP2 isoform and control shRNAplasmids are deﬁned in Supplementary infor-
mation. (b) Samples in (a) were probed with Smad2, Smad3, Smad7, vimentin and actin
antibodies as indicated and blots developed using ECL reagent. Smad-speciﬁc
Western blots were quantiﬁed by densitometric scanning and values were standard-
ized for β-actin expression. (c) Cells were grown for 48 h in the absence or presence
of tet and serum starved for 16 h. Colo-357 cells were treated with TGFβ at 0.5 ng/ml
for 48 h, or were left untreated. At the relevant time point, cell growth/survival was
assessed using the CellTiter Cell Proliferation Assay (Promega, UK).
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a C-terminal isoform containing the HECT catalytic domain and
WW4 domain (WWP2-C). Each isoform carries unique modular
and structural features that determine substrate binding speciﬁcity
and functional activity that can ﬁne-tune the levels of both
activating and inhibitory Smads and thereby control EMT, a differentia-
tion programme associated with cancer cell spread and metastasis.
To address their functional and disease-speciﬁc roles, we examined
the effect of stably modulating WWP2 isoform expression levels in the
Colo-357 carcinoma cell line using shRNA constructs speciﬁc for each
individualWWP2 isoform. Each transcript is generated via intron re-
tention or alternate promoter use, and these unique 3′/5′-
untranslated sequences have enabled us to experimentally assess
and manipulate expression of each isoform individually using
speciﬁc shRNA plasmids. We isolated two WWP2-FL clones and
three WWP2-N clones and, following doxycycline induction, cell
lysates were probed by western blotting for expression levels of
WWP2, Smads, and the EMT marker vimentin. Based on western
blots using antibodies against both C- and N-terminal epitopes in
WWP2 combined with molecular weight comparisons, we found
variable degrees of knockdown in the WWP2-FL and WWP2-N
clones (Fig. 1a). In the WWP2-C clone we were unable to detect
any speciﬁc WWP2-C band on western blots reﬂecting previous
ﬁndings that expression of WWP2-C is not detectable at the mRNA
level in colo-357 cells [9], and this provides a useful shRNA control
for WWP2-FL and WWP2N levels. Although overall doxycycline
inducibility using this particular system is modest, we do see
reasonable (although not complete) knockdown of WWP2-FL in
clones FL-1 and FL-2. Similarly, in the WWP2-N clones there is a
degree of inducible knockdown, and this is most apparent in clones
N1 and N3, and clone N1 has a low level of WWP2-N expression
with/without the inclusion of doxycycline. The reason for the
partial/variable inducibility seen with doxycycline probably reﬂects
inherent leakiness associated with this particular vector system
[14], and may also be a feature of the Colo-357 cell line used in this
study as reported previously [13,15]. The advantage in using this
approach is that in our hands it provides a robust and reliable stable
approach for selective knockdown, and overcomes artifactual effects
associated with transient siRNA knockdown as well as achieving a
degree of control in expression levels that can overcome any effect
on long-term cell survival/viability.
We next probed these samples for the expression of the EMTmarker
vimentin, as well as actin as a control to compare expression levels in
the presence/absence of doxycycline. The most striking observation
from this analysis is that all three WWP2-N clones constitutively
express high levels of the EMT marker vimentin, although we do not
observe an obvious doxycycline-induced response in these cells
(Fig. 1b). We then probed cell lysates using Smad-speciﬁc antibodies,
and scanned and quantitated these blots to look for emerging patterns
of Smad2, Smad3 and vimentin expression across the WWP2 isoform
knockdown clones. Interestingly, we consistently ﬁnd that the ratio of
Smad3 levels relative to Smad2 is signiﬁcantly affected. Whilst this
ratio is close to 1 in WWP2-FL and control cells, there is signiﬁcantly
more Smad3 protein levels in the WWP2-N knockdown cells, and the
highest ratio is 5:1 Smad3:Smad2 in clone N2 (Fig. 1b). In clones N2
and N3, there is also a lower level of Smad7 protein. Interplay between
Smad 2,3 and 7 is complex and dynamic, and R-Smads can directly
regulate I-Smad7 gene expression as part of an intrinsic feedback regu-
latory loop [16]. In addition, the lower endogenous Smad7 levels in
clones N2 and N3 in particular, might reﬂect the more overt imbalance
inWWP2-FL andWWP2-N ratios in these cells, releasingmoreWWP2-
FL away from R-Smads and re-directing it towards its alternative sub-
strate Smad7. Collectively, the data presented in Fig. 1b suggest that
reduced expression of endogenous WWP2-N results in higher protein
levels of R-Smad3 relative to R-Smad2, and spontaneous induction of
the EMT marker vimentin. Although the intermediate ﬁlament proteinvimentin is an established indicator ofmesenchymal transition Analysing
other EMT markers including Snail2, ﬁbronectin as well as vimentin by
qPCR in WWP2-N depleted cells supports the changes we ﬁnd using
western blotting of vimentin in cell lysates (Supplementary Fig. 1).
We next examinedwhether knockdown ofWWP2-FL andWWP2-N
affected growth/survival using cell proliferation assays. Following
induced knockdown with doxycycline and treatment with TGFβ,
WWP2-FL knockdown cells proliferated at a signiﬁcantly greater
rate compared to control cells, whereas WWP2-N knockdown cells
demonstrated similar rates of proliferation compared to control
cells (Fig. 1c). These data therefore suggest that subtle changes in
the levels of individual WWP2 isoforms can both stimulate and/or
inhibit cell proliferation and in a TGFβ-dependent manner. This
may reﬂect dose-dependent WWP2 auto-ubiquitination as reported
previously [17], and is also likely to be linked to inter-dependent
WWP2-FL/WWP2-N activation mechanisms [9].
Since an important aspect of WWP2 isoform function relates to
substrate speciﬁc interactions between -PPXY- motifs within individual
Smads and theWWdomains inWWP2,we next askedwhether expres-
sion of the isolated WW1 or WW4 domains could impact on TGFβ
signalling activity. Here, we used the CAGA12-luc luciferase reporter
plasmid to measure effects on Smad3-dependent gene expression and
found that expression of the isolated WW1 or WW4 domains in the
presence of WWP2 also signiﬁcantly inhibited Smad3 transcriptional
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Colo-357 cells stimulated to undergo EMT in the presence of TGFβ,
and found dose-dependent decrease in vimentin expression compara-
ble with the effect seen in the presence of either WWP2-FL or WWP2-
N expression (Fig. 2b). Taken together, these data suggest that the
WWP2-WW1 domain that is present in both WWP2-FL and WWP2-N
is sufﬁcient to mediate the WWP2-N-mediated suppression of TGFβ-
induced biological responses.3.2. A melanoma V717M-WWP2 mutant has altered Smad speciﬁcity and
forms a stable complex with WWP2-N
Since WWP2-N has been shown to form a complex with WWP2-FL
and thereby activate WWP2-FL ubiquitin ligase activity, we next
searched for examples of WWP2 mutations that might disrupt this
regulatory interaction using the COSMIC Catalogue of Somatic Mutations
in Cancer database that has recently been used to identify and catalogue
cancer-speciﬁc intragenic mutations [18]. Interestingly, a single mutated
form of WWP2 was found in the MZ7-mel melanoma cell line that has a
single valine-to-methionine point mutation (V717M-WWP2), although
a more recent COSMIC update has reported 7 additional mutations
including three in primary cancer tissue from lung, one in breast, one
in ovary and two in upper aero-digestive tract [19]. Whilst we cannot
directly infer oncogenic roles for individual examples of WWP2 mutants
in cancer, they doprovide a framework for selectingpotentially oncogenic
mutations inWWP2 formore detailed structure/functional insight analy-
ses. We therefore analysed V717M-WWP2 to see whether it exhibitedFig. 2. WWP2 WW1 domain suppresses Smad/TGFβ-dependent biological responses.
(a) HEK 293 cells were transfected using the transfection reagent LipoD293™ (SignaGen)
according to the manufacturer's instructions and incubated 48 h. After TGF-β stimulation
(6 h), cells were lysed and assayed for luciferase and β-galactosidase activity using the
Luciferase Reporter Assay (Promega) and the Beta-Glo System (Promega) respectively,
as outlined previously (Soond and Chantry, 2011b). For each transfection, 0.25 μg of the
Smad3 reporter plasmid (pCAGAC12-luc) was used and, where indicated, the following
expression vectors were added: Smad3 (0.25 μg), Smad7 (0.1 μg), WWP2 (0.1 μg),
WW1 (1 μg), and WW4 (1 μg). In addition, for detection of Smad3-speciﬁc activity,
7.5 ng of pRSV-β-galactosidase (pRSV-βgal) encoding plasmid was added. Values for
luciferase activity were standardised for β-galactosidase activity and expressed as
fold over basal activity. Values represent means ± SD. (b) Colo-357 cells were
transfected with the indicated doses of expression plasmids encoding Flag-tagged
WW1 domain, 24 h after TGFβ stimulation. Cells were TGFβ stimulated for a further
48 h post-transfection, harvested and whole cell lysates assessed for vimentin and
β-actin expression by Western blotting.any altered activity towards Smads and WWP2-N in the context of
TGFβ-dependent functional responsiveness.
Firstly, using CAGA-luc reporter assays we found that V717M-
WWP2-FL is less effective than WWP2-FL-WT in inhibiting Smad3-
dependent gene expression (Fig. 3a), and also has reduced Smad3-
speciﬁc ubiquitin ligase activity in the presence of WWP2-N based
on in vitro ubiquitination assays (Supplementary Fig. S2). We then
used the WWP2-N knockdown Colo-357 cells to assess the activity
of WWP2-V717M in the context of WPP2-N expression using
TGFβ-induced vimentin expression as a biological readout. Firstly,
it is noteworthy that the re-expression of WWP2-N into WWP2-N
knockout cells repressed vimentin expression (Fig. 3b; top panel
lane 1 compared with lane 4), supporting the notion that WWP2-N
could have a key role to play in EMT-associated events. Furthermore,Fig. 3. A melanoma WWP2-V717M and WWP2-N co-operate to stabilize Smad3 depen-
dent gene transcription and enhance TGFβ-induced vimentin expression. (a) For eachplas-
mid transfection, 250 ng Smad3 reporter CAGAC12-luc and 15 ng pRSV-β-galactosidase
(pRSV-βgal) encoding plasmid was used in conjunction with Smad encoding plasmids.
Values were averaged, luciferase activity standardized for β-galactosidase activity and
data expressed as relative fold changes in luciferase activity over basal activity.
(b) WWP2-N−/− Colo-357 cells were transfected with expression plasmids encoding
Flag-tagged WWP2-N, WWP2-FL-WT or WWP2-FL-717M as indicated. Cells were stimu-
lated with 2 μM doxycycline, +/−TGFβ for 48 h, and cell lysates western blotted as
indicated.
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doxycycline/TGFβ we found a signiﬁcantly higher level of vimentin
expression in cells transfected with WWP2-V717M compared with
WWP2-WT (Fig. 3b; lane 6 compared to lane 5). The lower levels
of Flag-WWP2-N expressed in cells transfected with FL-WWP2
(Fig. 3b; lanes 2 and 3 compared with lane 1) might reﬂect the role
of WWP2-FL in inﬂuencing both its own auto-ubiquitination and
WWP2-N ubiquitination stability as noted previously [9], although
this does not affect the direct comparison of WWP2-FL-WT and
WWP2-FL-V717M in these experiments in which we ﬁnd similar
levels of WWP2-N-Flag expression levels. It is also noteworthy that
re-expression of WWP2-FL (or mutant) suppressed vimentin levels
in unstimulated cells (Fig. 3b; lanes 2–3, and 5–6), and we thinkFig. 4.WWP2-V717M has altered speciﬁcity for WWP2-N and Smads. (a) HEK293 cells were t
100 ng WWP2-FL-Flag, WWP2-FL-V717M-Flag or WW2-N-Flag as indicated. Cells were pre-t
were cleared by centrifugation and samples immunoprecipitated using anti-HA antibody and
Laemlli buffer (+10 mM DTT) followed by Western blot analysis as indicated. (b) HEK-293
WWP2-FL-Flag or WWP2-FL-V717M-Flag expression plasmid with the indicated increasing a
empty vector pRK5). After 48 h including 3 h MG132 +/− TGFβ, whole cell lysates were h
with 1 μg HA-tagged Smad3 in the presence/absence WWP2-N-Flag and were pre-treated wit
MG132 and in the presence of cycloheximide (20 μg/ml) and +/−TGFβ stimulation
Smad3 and Flag antibodies. (d) HEK-293 cells were transfected with 1 μg of WWP2-FL
FL-V717M-Flag and WWP2-N-Flag as indicated. After 48 h, cells were pre-treated wit
immunoprecipitated with anti-HA antibody or WWP2-C terminal speciﬁc antibody andthis is due to enhanced activation of over-expressed WWP2-FL by
the residual WWP2-N in these cells.
Next, we expressed WWP2-WT and WWP2-V717M in HEK-293
cells in the presence of HA-tagged ubiquitin to compare the relative
capacity for these ligases to stimulate ubiquitination of total cellular
proteins in the presence/absence of WWP2-N. Interestingly, WWP2-
V717M appears to be more active in the presence of Smad2 and
signiﬁcantly less active in the presence of Smad3 (Fig. 4a). Further-
more, the activity of WWP2-V717M in the presence of WWP2-N is
signiﬁcantly lower in the presence of Smad3, and in HA-ubiquitin
immunoprecipitates we ﬁnd a TGFβ-inducible association of WWP2-N
in the presence of WWP2-FL-WT and Smad2 or Smad3, but not in the
presence of WWP2-V717M-FL and Smad3 (Fig. 4a). Collectively theseransfected with 1 μg Flag-tagged Smad2 or Smad3 as indicated, 100 ng HA-ubiquitin and
reated with MG132 for 5 h and then stimulated with TGFβ as indicated, and cell lysates
protein-G agarose. Immunoprecipitates or whole cell lysates were resuspended in 15 μl
cells were co-transfected with 1 μg of Smad3-Flag expression plasmid and 0.25 μg of
mounts of WWP2-N-Flag expression plasmid (DNA amounts were kept equivalent using
arvested and analysed by anti-Flag Western blotting. (c) HEK293 cells were transfected
h MG132 for 5 h. Cells washed in fresh growth medium and incubated in the absence of
for the time-points indicated. Whole cell lysates were blotted and probed with
-HA expression construct (or empty vector control) together with 1 μg of WWP2-
h MG132 for 5 h, and then stimulated (+/−5 ng/ml TGFβ for 1 h). Lysates were
blots probed with anti-Flag anti-HA as indicated.
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terconnections in these complexes, the WWP2-V717M mutant does be-
have very differently towards Smad3, particularly in the context of
WWP2-N expression. To test whether this altered substrate speciﬁcity
for Smad3 affected its stability, we next examined Smad3 steady-state
levels in the presence of increasing amounts of WWP2-N. Dose-
dependent WWP2-N expression induced a signiﬁcant reduction in
Smad3 steady-state levels as reported previously [9]; however Smad3 is
much more stable in the presence of WWP2-V717M compared to
WWP2-WT (Fig. 4b). Although no difference was seen in the pres-
ence/absence TGFβ using this approach, using cycloheximide
chase studies there is a clear TGFβ-dependent stabilization of
Smad3 levels in the presence of WWP2-V717M compared with
WWP2-WT (Fig. 4c). We next assessed WWP2-FL interactions
withWWP2-N and found that, unlikewild-typeWWP2-FLwhich disso-
ciates fromWWP2-N following TGFβ stimulation [9], V717M-WWP2-FL
forms a strong stable complexwithWWP2-N in the presence/absence of
TGFβ (Fig. 4d). Therefore, these data suggest that V717M-WWP2 has a
unique capacity to capture and retain R-Smad3 both in the presence/ab-
sence of TGFβ, and that this complex leads to subsequent Smad3 stabili-
zation in TGFβ stimulated cells.
Currently, and based on the lack of any 3-dimensional structures for
WWP2, we are not yet able to mechanistically rationalize these func-
tional complexities that are unique for WWP2-V717M in the context
of its interactionswithWWP2-N and altered Smad substrate speciﬁcity.
However, it is interesting to note that 3Dmodelling of WWP2 based on
the known structure of the relatedWWP1 ubiquitin ligase suggests that
the V717M mutation occurs at a critical point on a structural fold close
to the active site that may play a key role in substrate recognition
(see Supplementary Fig. S3), and also impact onN-/C-terminal intramo-
lecular interactions within WWP2 reported previously [9,20].
3.3. DifferentialWWP2 isoform expression in human breast/prostate cancer
and melanoma
Since WWP2 and its isoforms are emerging as potential oncogenes
with deﬁned biological activities, we next conducted a comprehensive
WWP2 isoform expression analysis using cDNA arrays from normal
and diseased human cancer tissues. Our studies have focused on
qRT-PCR using isoform-speciﬁc probes that detect unique 5′/3′
sequences in each individual transcript since there are currently
no antibodies available that can distinguish protein levels of indi-
vidual WWP2 isoforms. For this transcript analysis, we examined
normal and diseased tissue isolated from breast cancer, prostate
cancer, and melanoma. Comparison of WWP2-FL, WWP2C, and
WWP2-N expression proﬁles showed unique patterns of mRNA
expression in several of the diseased samples relative to normal
(Fig. 5A). We also found instances of high (N4-fold) WWP2-FL
expression (3/10) and WWP2-C (2/10) in breast cancer stage I,
relative to normal breast tissue. We then performed one-way
ANOVA analyses of variance to identify broad differences in cancer
expression patterns among different disease stages for the three
WWP2 isoforms. Signiﬁcant differences were found for WWP2-N
in prostate cancer and melanoma (Fig. 5B), and post-hoc tests indi-
cated that WWP2-N expression was signiﬁcantly lower in stage IIIC
compared to stage II melanoma and signiﬁcantly higher in stage II/
III prostate cancer relative to normal tissue (Tukey HSD, p b 0.05;
Supplementary Fig. S4).
4. Discussion
In this study, we have addressed the role of individual WWP2
ubiquitin ligase isoforms in the regulation of TGFβ-induced EMT using
stable shRNA knockdown experiments in Colo-357 cells. Interestingly,
we ﬁnd that the WWP2-N isoform generated by retention of intron 9/
10 during splicing of theWWP2 gene transcript, has the unique capacityto suppress endogenous expression levels of EMT markers, and that
this is likely to be due to its ability to differentially target un-stimulated
R-Smads2/3 for degradation. Therefore, we suggest that a key role for
WWP2-N in particular might be as a novel metastasis suppressor gene
product through its ability to suppress the normal TGFβ-induced differ-
entiation programme associated with EMT and cancer metastasis.
This is supported by the functional interaction of WWP2-N with a novel
melanoma-speciﬁc WWP2-V717M mutant that was found to have
altered speciﬁcity towards Smad3 causing stabilization of Smad3 protein
levels. Using cDNA arrays we have also shown that WWP2-N isoform
expression patterns differ signiﬁcantly in early/late stages of melanoma
and prostate cancer, and note several examples of high WWP2-FL and
WWP2-C isoform expression in breast cancer.
The type of robust and stable shRNA-based knockdown system
we have used in this study has several advantages over transient
siRNA approaches when studying long-term differentiation programmes
such as EMT. There is however a degree of leakiness with this system as
reported by others [14], and this has also been found previously using
the Colo-357 cell line [13,15].Whilst we do see partial doxycycline induc-
ibility of WWP2-FL and WWP2-N knockdown in some of our stable cell
clones, there is still a signiﬁcant reduction overall in these isoforms rela-
tive to control cells. It was therefore surprising to ﬁnd no doxycycline
inducibility in terms of the effect of WWP2-N knockdown on spontane-
ous vimentin expression. Whilst this may be partially explained by the
system leakiness, it could reﬂect a degree of threshold-dependent or all-
or-nothing signalling involved in Smad/TGFβ-dependent induction of
EMT and vimentin expression, perhaps linked also to inherent vimentin
stability when incorporated into intermediate ﬁlaments [21]. Threshold
Smad signalling related to differential biological outputs has been noted
previously [13,22], and this has been linked to TGFβ ligand gradients
in vivo [23]. Therefore, we speculate that only a small drop in the expres-
sion level of an intrinsic Smad regulator such as WWP2-N could be sufﬁ-
cient to tip the homeostatic balance, that then triggers the onset of
downstream TGFβ-regulated transcription factors such as Snail and
Twist [10], and then drive the EMT differentiation programme through
to completion. Furthermore, we suggest that only a small drop
in WWP2-N could be sufﬁcient to tip the balance in its effect on
endogenous WWP2-FL activity, and any subsequent effect on Smad-
dependent vimentin expression.Wedo know fromour previous studies
thatWWP2-N has a striking dose-dependent effect onWWP2-FL activ-
ity, and that this also leads to increased WWP2-FL auto-
ubiquitination and turnover. Others have also noted that WWP2
activity is very dose-dependently sensitive, and is affected signiﬁ-
cantly by subtle changes in overall WWP2 expression levels [17].
An interesting observation to emerge from our analysis of the
WWP2-N knockdown cells is the dramatic increase in the expres-
sion ratio levels of Smad3 relative to Smad2. The vimentin promoter
has been studied previously and is known to respond exclusively to
Smad3 overexpression, and not Smad2 [24]. Therefore, increasing rela-
tive Smad3 levels seen WWP2-N knockdown cells could partially
explain the spontaneous vimentin expression. Colo-357 cells are
known to display a small level of endogenous autocrine TGFβ activ-
ity [15], sufﬁcient to trigger vimentin promoter activity and in the
context of elevated Smad3 protein levels. At present, it is not clear
why WWP2-N knockdown would selectively impact on Smad3
levels relative to Smad2. However, we have noted previously that
Smad3 ubiquitination is more pronounced than Smad2 in the
presence of WWP2-FL and WWP2-N [9]. Furthermore, in this study
it is apparent that ubiquitination of cellular proteins in the presence
of WWP2-FL differs signiﬁcantly in Smad2 and Smad3 over-
expressing cells (Fig. 4a). EMT-based studies in cell lines derived
from Smad2 and Smad3 null mice also suggest that higher relative
levels of Smad2 can suppress EMT in hepatocytes [25], and a domi-
nant role for Smad3 compared to Smad2 has been reported previ-
ously in the context of breast cancer bone metastasis [26]. In
addition, speciﬁc ablation and lowering of relative Smad2 expression
2133S.M. Soond et al. / Biochimica et Biophysica Acta 1832 (2013) 2127–2135levels increased EMT during skin cancer formation and progres-
sion [27].
The switch from high to lowWWP2-N expression between stage III
to IIIC seen in melanoma, and the distinct role that we ﬁnd for the
WWP2-V717M melanoma-speciﬁc mutant in the context of WWP2-N
function, suggests that the WWP2-N isoform could potentially contrib-
ute in part to signallingmechanisms drivingmelanomaprogression and
metastasis. This process has been associated with increased TGFβ ex-
pression and activity [28]. Since TGFβ has a dual role in cancer and
can also act in key growth inhibitory and tumour suppressive pathways,
it is interesting to speculate that tumours expressing high WWP2-N
levels that we predict would encourage spontaneous R-Smad turnoverFig. 5. Expression ofWWP2 isoforms in breast/prostate cancer and melanoma. (A)WWP2 isofo
array panels consisted of breast cancer cDNA derived from normal (n = 7), stage I (n = 10), sta
from normal (n = 3), stage III (n = 10), stage IIIA (n = 1), stage IIIB (n = 6), stage IIIC (n = 4
(n = 3), and non-recorded hyperplasia/prostatitis (n = 31). (B) Results of regression analyses
cancer and melanoma. Signiﬁcant (p b 0.05) relationships are highlighted in bold. Actual WW
mean +/− standard error is presented in the Supplementary data (Fig. S1).in the absence of TGFβ, for example aswe have found in prostate cancer,
might be driven by cellular events associated more with a loss of the
TGFβ growth arrest response linked tumour initiation and outgrowth
rather than EMT/metastasis. In support of this notion, TGFβ signalling
through Smad4 has recently been shown to act as a barrier that con-
strains prostate cancer growth and metastatic progression [29].
Overall, although we acknowledge that many more patient samples
need to be assessed and analysed, our results suggest thatWWP2 could
be a potential cancer biomarker. Furthermore, based on our observa-
tions that small isolated WW domain peptides derived from WWP2
can block TGFβ signalling activity, we predict that WWP2 might also
have utility as a molecular therapeutic target. We postulate thatrm expression analysis in primary tumour samples using real-time qRT-PCR analysis. The
ge IIA (n = 13), stage IIB (n = 7), stage IIIA (n = 8), stage IIIC (n = 3);melanoma cDNA
), stage IV (n = 19); prostate cancer cDNA from normal (n = 7), stage II (n = 7), stage III
of the relationships betweenWWP2 isoform expression between stages in breast/prostate
P2 isoform mRNA expression levels in normal and cancer disease stages expressed as
Fig. 6. Proposed role for WWP2 isoforms in TGFβ-induced cancer cell growth and invasion. In early-stage cancer mis-expression of the WWP2-N isoform activates WWP2-FL to induce
Smad2/3 degradation. This overcomes normal TGFβ-mediated growth arrest, and triggers cancer initiation and outgrowth. Subsequently, increased expression of WWP2-C and/or
WWP2-FL can cause inhibitory Smad7 degradation and decreased WWP2-N can stabilize Smad3 levels, both events switching on pro-metastatic TGFβ functions including EMT. Somatic
mutants such as WWP2-V717M displaying altered speciﬁcity towards Smad3 could also drive EMT and cancer metastasis.
2134 S.M. Soond et al. / Biochimica et Biophysica Acta 1832 (2013) 2127–2135WWP2-N could serve as a key suppressor of events associated with
the initiation of EMT and metastasis, and likely reﬂects the unique
ability of this particular WWP2 isoform to limit the levels of R-
Smads in cells that have not encountered TGFβ, and thereby could
act normally to restrain the onset of TGFβ-induced EMT. These ob-
servations could be signiﬁcant in the context of tumour initiation/
progression linked to aberrant TGFβ signalling activity, and suggest
that tumours expressing low levels of theWWP2-N isoform could be
more aggressively driven through a cycle of EMT/metastasis. Simi-
larly, in high WWP2-FL and WWP2-C expressing tumours we antic-
ipate that inhibitory I-Smad levels will be attenuated, again
perpetuating high TGFβ activity and EMT (Fig. 6). Our current work-
ing hypothesis is that the WWP2 gene locus represents an entirely
novel ‘self-contained’ TGFβ regulatory module that incorporates a
hand brake (WWP2-N and pre-clearance of activating Smads), a
central ubiquitin ligase engine (WWP2-FL), and an accelerator
(WWP2-C and clearance of inhibitory Smads). All components are
generated from a single gene locus through the use of internal
intronic promoters, and by the regulation of RNA splicing events
that determines whether speciﬁc introns are retained in the mature
transcript leading to incorporation of premature stop-codons.
Futureworkwill address splicing and transcriptionalmachinery that
determines the balance of WWP2 isoform expression, and full elucida-
tion of the precise molecular mechanisms responsible for WWP2
isoform functional interconnections between TGFβ signalling and
wild-type as well as cancer-speciﬁc WWP2 mutants will be facilitated
by ongoing 3D structural approaches. To unequivocally validate WWP2-
N as a potential new metastasis suppressor gene, a long-term goal is
to establish knockout mice in which intron 9/10 of the WWP2 gene is
deleted so that WWP2-N can no longer be generated in vivo.Acknowledgements
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